Overview
TScan Q3 2025 revenue rose to $2.5 mln, driven by collaboration agreements
Net loss for Q3 2025 increased due to higher R&D expenses
Company reached FDA agreement on pivotal trial design for TSC-101
Outlook
Company expects cash reserves to fund operations into the second half of 2027
Enrollment in solid tumor trial paused to focus on preclinical development
Result Drivers
R&D EXPENSES: Research and development (R&D) expenses for the third quarter of 2025 were $31.7 million, compared to $26.3 million for the third quarter of 2024
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Collaboration and License Revenue | $2.51 mln | ||
Q3 Net Income | -$35.71 mln | ||
Q3 Basic EPS | -$0.28 | ||
Q3 Income From Operations | -$37.05 mln | ||
Q3 Operating Expenses | $39.56 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for TScan Therapeutics Inc is $6.00, about 79.7% above its November 11 closing price of $1.22
Press Release: ID:nGNX9WGD6S
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)